Substance withdrawal syndrome
Drug research and approvals for substance withdrawal syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 11 studies of substance withdrawal syndrome are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 11
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Cerebral Physiology of NOWSNCT07610746 · Not applicable · Indiana University · starts Aug 11, 2026
- IWS Diagnosis Criteria ConsensusNCT07316894 · Not reported · ELIAS Emergency University Hospital · starts Dec 13, 2025
- Target Trial Emulation for Pharmacologic Treatment of Neonatal Opioid Withdrawal SyndromeNCT07278375 · Not reported · HELP for NOWS Consortium · starts Dec 9, 2025
- Validation of the French Version of the Prediction of the Alcohol Withdrawal Severity Scale (PAWSS)NCT06675539 · Not reported · Etablissement Public de Santé Barthélemy Durand · starts Nov 11, 2024
- Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use…NCT06538558 · Phase 1 · Proniras Corporation · starts Oct 16, 2024
- Evaluation of the Electronic Cigarette Withdrawal SyndromeNCT06066996 · Early Phase 1 · Johns Hopkins University · starts Nov 28, 2023
- MicroRNA Biomarkers for Neonatal Opioid Withdrawal SyndromeNCT05937594 · Not reported · Milton S. Hershey Medical Center · starts Jan 15, 2020
- Kratom Use Disorder Management Using Clonidine and/or BuprenorphineNCT05883358 · Not reported · Salem Anaesthesia Pain Clinic · starts Jul 2, 2018
- Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3NCT05834478 · Phase 3 · Emory University · starts Feb 20, 2024
Approved 1
- LofexidineAdrenergic receptor alpha-2 agonist
Phase 3 5
- BaclofenGABA-B receptor agonist
- BuprenorphineMu opioid receptor agonist
- NaloxoneOpioid receptors; mu/kappa/delta antagonist
- ChlordiazepoxideGABA-A receptor; anion channel positive allosteric modulator
- LevetiracetamSynaptic vesicle glycoprotein 2A modulator
Phase 2 5
- OxytocinOxytocin receptor agonist
- GabapentinVoltage-gated calcium channel modulator
- TramadolMu opioid receptor agonist
- LorazepamGABA-A receptor; anion channel positive allosteric modulator
- Prasterone
How its trials ended
150 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 28 whose ending is known, 39% met their primary endpoint, 7% missed it and 54% stopped early.
- Completed, result not reported8255%
- Ongoing2617%
- Status unknown149%
- Met its primary endpoint117%
- Stopped: other or unclear85%
- Stopped: enrollment or feasibility53%
- Missed its primary endpoint21%
- Stopped: lack of efficacy11%
- Stopped: funding11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA